Global and China focuses on Market Research Reports.Apart from providing market research reports we are also capable of providing customized services comprising of primary interviews and in-depth market surveys.Our primary focus is to provide the best in class, in-depth and reliable market data related to Chinese markets.
Sunday, 9 March 2014
China Chinese Patent Medicine Industry Report, 2013 - 2016
Currently, the State is enhancing its
support for the Chinese patent medicine industry, successively
introducing the Continuing Improving TCM Healthcare Policy, Notice on
Conducting Construction of Key Projects of TCM Trade in Services and
other favorable policies in 2013. In 2010-2013, China’s Chinese patent
medicine industry developed rapidly, with revenue soaring from RMB215.4
billion to RMB448.2 billion at a CAGR of 27.7%.
According to hospital terminal data,
Chinese patent medicine for the treatment of cardiovascular and
cerebrovascular diseases, tumor diseases and respiratory system diseases
are the top three categories of Chinese patent medicine in China,
respectively accounting for 37.2%, 15.4% and 11.1% market share in
2012-2013. As far as the distribution of Chinese patent medicine
formulations is concerned, there is a clear trend of convergence in
injection, and injection formulation products in the top three
categories of Chinese patent medicine all made up above 50%.
A rising tide of regulatory expectations, tougher inspection regime and
instant need of patient reporting has provided the much needed impetus
for the growth of the pharmacovigilance market. An upsurge in number of
acute and chronic diseases has consequently led to a rise in number of
drug consumption, which has also elicited a growth in the number of
adverse drug events and drug toxicity cases. Moreover, several
high-profile safety issues, regulatory warnings, large volume of events
to be reviewed along with negative media coverage have compelled the
pharmaceutical players to take support of various outsourcing services.
There are two major outsourcing services opted by these pharmaceutical
players i.e. traditional CROs and BPOs.
The report provides a detailed understanding and analysis of how and why
companies enter discovery, preclinical and clinical stage partnering
deals. The majority of deals are where the licensee obtains a right or
an option right to license the licensors product or compound. These
deals tend to be multicomponent, starting with collaborative R&D,
and commercialization of outcomes.The Discovery, Preclinical and Clinical Stage Partnering Terms and
Agreements in Pharma and Biotech report provides comprehensive
understanding and unprecedented access to the discovery, preclinical and
clinical stage partnering deals and agreements entered into by the
worlds leading healthcare companies.
Cardiovascular and cerebrovascular
disease market is the biggest market for Chinese patent medicine, but
also the most-variety field with item sales of over RMB500 million. The
representative products include ginkgo leaf injection, Shuxuetong
injection, Danhong injection, Xingnao injection, and more.
In the international market, there is a
higher recognition of Chinese patent medicine in Asia, especially in
Southeast Asia, and many varieties of Chinese patent medicine are
included in the Medicare drug list stipulated by Southeast Asian
countries, and special departments are established for management
research as well.
For More Information Kindly Contact: Email: email@example.com Web Site: http://www.researchmoz.us/ Blog: http://globalandchinamarket.blogspot.com